---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-25-000081"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:39:05.390939+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arvinas cuts workforce 33%, reports positive VERITAC-2 data, removes two Phase 3 combo trials

## Summary
- Positive topline results from Phase 3 VERITAC-2 trial of vepdegestrant in 2L+ ER+/HER2- metastatic breast cancer; data accepted for ASCO 2025.
- Workforce reduction of ~33% across all areas; expects ~$10M in severance costs, substantially complete by end of Q2 2025.
- Removed two planned Phase 3 combination trials (first-line with atirmociclib and second-line with CDK4/6 inhibitor) from vepdegestrant plan.
- Cash, cash equivalents and marketable securities of $954.3M as of March 31, 2025; runway extended into H2 2028.
- ARV-102 Phase 1 data demonstrated blood-brain barrier penetration and >50% LRRK2 reduction in CSF at 60 mg single dose.

## SEC filing metadata
- accession: 0001655759-25-000081
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000081/0001655759-25-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000081/arvn-20250430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-25-000081
- JSON: https://secwatch.observer/filing/0001655759-25-000081.json
- Plain text: https://secwatch.observer/filing/0001655759-25-000081.txt

## Key facts
- Restructurings & Charges
  ARVINAS, INC. announced a restructuring with charges of approximately $10 million affecting all areas of the Company (approximately 33%).
  - Type: restructuring
  - Charge: approximately $10 million
  - Affected area: all areas of the Company
  - Headcount: approximately 33%
  source text: On April 30, 2025, the Company's management, pursuant to authority delegated by the Board of Directors of the Company, committed the Company to and approved a reduction of the Company’s workforce by approximately 33% across all areas of the Company, as part of the Company's decision to streamline operations across the organization and enable the efficient progression of the Company’s portfolio. The Company expects the workforce reduction will be substantially completed by the end of the second quarter of 2025. The Company expects that it will incur approximately $10 million in costs in connection with the workforce reduction, which consist of severance and other one-time employee termination benefit expenses, which the Company expects to recognize primarily in the second quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000081/0001655759-25-000081-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.